Clinicopathological Features of Gastroesophageal Neuroendocrine Neoplasms.
Mengyuan LiuElizabeta C PopaBrendan M FinnertyThomas J FaheyRasa ZarnegarPublished in: Current gastroenterology reports (2020)
Degree of differentiation and Ki-67 proliferation index are required for accurate classification of neuroendocrine tumors and carcinomas but not sufficient to distinguish between the two entities. Resection remains the mainstay treatment for early-stage gastroesophageal neuroendocrine tumors. Additional perioperative therapy may benefit mitotically active tumors. There is a role for somatostatin analogues, especially in the setting of metastatic and symptomatic disease. New radiolabeled somatostatin analogues, immunotherapy, and embolization offer multimodality treatments for distant metastases. We need to understand the specific underlying biology of the various subtypes of gastroesophageal NENs to provide tailored treatment.
Keyphrases
- neuroendocrine tumors
- early stage
- small cell lung cancer
- squamous cell carcinoma
- molecular docking
- patients undergoing
- signaling pathway
- stem cells
- deep learning
- neoadjuvant chemotherapy
- high grade
- mass spectrometry
- bone marrow
- mesenchymal stem cells
- replacement therapy
- molecular dynamics simulations
- structure activity relationship